文献速递泌尿生殖腹部介入CTUS

经皮影像引导实性肾肿块粗针活检:安全性、有效性、病理判读及临床意义分析

Percutaneous image-guided core biopsy of solid renal masses: analysis of safety, efficacy, pathologic interpretation, and clinical significance.
PubMed 文献 · Abdom Radiol (NY) · 2018-01-01

回顾性分析2002年3月至2012年12月183例连续患者经CT或US引导的肾肿块活检,184次活检中恶性126次(68.5%)、良性37次(20.1%)、无法诊断21次(11.4%);免疫组化在131次(71.1%)活检中施行,其中88.5%有诊断价值;恶性肿瘤检出敏感度、特异度和阳性预测值均为100%,良性诊断阴性预测值亦为100%;并发症共14次(7.6%),其中轻微13次(7.1%)、严重1次(0.5%)。

要点

  • 184次肾肿块活检中无法诊断21次(11.4%),免疫组化在131次(71.1%)活检中施行且88.5%有诊断价值。
  • 恶性肿瘤检出敏感度、特异度、阳性预测值均为100%,良性诊断阴性预测值亦为100%。
  • 并发症共14次(7.6%),轻微13次(7.1%)、严重1次(0.5%),未见肾假性动脉瘤或肿瘤种植。

核心结论

  • 经皮影像引导肾肿块活检联合免疫组化安全且诊断效能高,支持在制定适当治疗时扩大肾肿块活检和影像学的作用。

研究设计与样本

  • 回顾性、经IRB批准、符合HIPAA的队列研究,纳入2002年3月至2012年12月183例连续患者,其中14/183(7.7%)因在外院活检、病历不完整或病灶显示不佳被排除,10例因新发增大肿块多次活检,最终169例患者共184次活检。

诊断标准与关键数值

  • 184次活检中恶性126次(68.5%)、良性37次(20.1%)、无法诊断21次(11.4%);免疫组化在131次(71.1%)活检中施行,其中88.5%有诊断价值;28例后续行部分肾切除术,27/27(100%)活检与肾切除标本恶性诊断一致,21/27(77.8%)RCC亚型一致;恶性肿瘤检出敏感度、特异度、阳性预测值均为100%,良性诊断阴性预测值亦为100%。

临床应用与阅片要点

  • 采用US、CT或CT/US融合引导,将17G或19G套管针置于肿块边缘,以18G或20G粗针活检枪获取数条组织芯;肾实质内科疾病活检被排除。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To determine the efficacy, safety and clinical utility of CT and US-guided percutaneous renal mass biopsy.

MATERIALS AND METHODS: A retrospective IRB-approved, HIPAA-compliant study of a cohort of 183 consecutive patients who underwent percutaneous, CT or US-guided renal mass biopsy (RMB) from March 2002 through December 2012 was performed. RMB was performed in 183 consecutive patients for suspected solid renal mass of whom 14/183 (7.7%) were excluded because biopsies were performed at an outside institution, medical records were incomplete, or lesions were poorly visualized. Ten patients had multiple biopsies for new growing masses. Using US, CT or CT/US fusion-guidance, a 17G or 19G cannula needle was placed at the margin of the mass and an 18G or 20G core biopsy gun was used to obtain several tissue cores. Renal parenchymal biopsies for medical renal diseases were excluded. Imaging variables (including size, location, and extent of disease), number of core biopsies, patient demographics (age, gender), clinical indication, final pathologic diagnosis, immunohistochemical (IHC) studies, and subsequent final pathological diagnosis on nephrectomy were evaluated.

RESULTS: Of the 169 patients with 184 RMB, 121/169 (71.6%) were male with a mean age of 67.5 years. Of 184 RMB, 126 were malignant [126/184 (68.5%)], 37 [37/184 (20.1%)], were benign, and 21 (21/184 (11.4%) were nondiagnostic. IHC was performed in 131 biopsies (71.1%) and was diagnostic in 88.5% of those cases. Twenty-eight patients underwent subsequent partial nephrectomy; in 27/27 (100%) cases, RMB was concordant with nephrectomy for malignancy and in 21/27 (77.8%) RMB was concordant for subtype of RCC. Overall, the RMB sensitivity for detection of malignancy, specificity, and positive predictive value were 100%. The negative predictive value of benign RMB diagnosis was also 100%. There was a total of 14 (7.6%) complications, 13 minor (7.1%) and 1 major (0.5%). Of the minor complications, ten (5.5%) were postprocedural minor hematomas that resolved conservatively; one (0.5%) postprocedural vasovagal reaction; one (0.5%) episode of hematuria; and one (0.5%) episode of nausea and abdominal discomfort. No cases of renal pseudoaneurysm or tumor seeding attributed to biopsy were identified.

CONCLUSION: Percutaneous image-guided RMB is safe and highly diagnostic when combined with IHC and supports a greater role of RMB and imaging in evaluating renal masses when rendering appropriate treatments.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Alle N, Tan N, Huss J, et al. Percutaneous image-guided core biopsy of solid renal masses: analysis of safety, efficacy, pathologic interpretation, and clinical significance. Abdom Radiol (NY). 2018. PMID: 29079986. doi:10.1007/s00261-017-1337-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。